Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn’s Disease

Shots:

• The P-ll SERENITY study involves the assessing of Mirikizumab (200mg, 600mg, 1000mg) vs PBO in patients in the ratio of 2:1:1:2 with moderately to severely active CD. The P-II study includes 12wks. induction period and 40wks. continued treatment period, evaluating the safety and efficacy of multiple dosing regimens and two methods of administration @52wks.
• Result: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the SC group), presented at UEG Week 2020
• Mirikizumab is a humanized IgG4 mAb that binds to the P19 subunit of interleukin 23 and being studied for the treatment of immune diseases, including psoriasis, UC, & CD
  
  Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bless Ayurveda